Clinical Trials
99 trialsEDS01 HN
West China Hospital
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
PICC-3
Sun Yat-sen University
LIGHT
Sun Yat-sen University
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
neoR-TORCH
Shanghai Chest Hospital
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Sun Yat-sen University
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
TRIPLE-PATH
Jinling Hospital, China
Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
EC-CRT-008
Sun Yat-sen University
FACT-TN
Sun Yat-sen University
WOLF
University of Pittsburgh
TORCH-iTNT
Fudan University
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
NEOTRIO-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Icahn School of Medicine at Mount Sinai
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
First Affiliated Hospital of Zhejiang University
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
First Affiliated Hospital of Zhejiang University
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Shandong Cancer Hospital and Institute
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Sun Yat-sen University
LungTime-C02
Hunan Province Tumor Hospital
PICC
Sun Yat-sen University
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Shanghai Chest Hospital
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
First Affiliated Hospital of Zhejiang University
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
First Affiliated Hospital of Zhejiang University
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
Guangdong Provincial People's Hospital
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Xijing Hospital
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Eye & ENT Hospital of Fudan University
Toripalimab With Chemotherapy for Sinus Cancer
Dana-Farber Cancer Institute
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Sichuan University
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
Eye & ENT Hospital of Fudan University
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
Peking University Cancer Hospital & Institute
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
Ruijin Hospital
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
First Affiliated Hospital of Zhejiang University